Abstract
A82846B, produced by Kibdelosporangium aridum, is a vital precursor for the semi-synthetic glycopeptide antibiotic Oritavancin. However, natural production yields a mixture of A82846A, B, and C, with the halogenation step acting as a significant bottleneck. This study describes the metabolic engineering of K. aridum SIPI-3927 to enhance A82846B titer and purity. By inserting an artificial attB site into the genome and overexpressing halogenase (orf10) and glycosyltransferase (orf11) genes, researchers developed the strain SIPI-3927-C6. In a 5-L fermenter, this strain achieved an A82846B yield of 2520 mg/L and a purity of 86.5%, representing a significant advancement for industrial production.
The Challenge of A82846B Biosynthesis
The production of Oritavancin, used to treat serious infections like MRSA, relies on the high-purity supply of its precursor, A82846B. Naturally, K. aridum produces three similar components: A82846A, B, and C. The "B" form is the desired intermediate, but the natural biosynthetic pathway is inefficient. Specifically, the halogenation step—responsible for adding chlorine atoms to the molecular backbone—is a major bottleneck. This leads to high levels of "A" and "C" impurities, which complicates and increases the cost of industrial purification.
Engineering a Genomic "Landing Pad"
A significant technical hurdle in engineering K. aridum is its lack of natural genomic "docking sites" (attB sites). These sites are typically required by the ΦC31 integration system to stably insert new DNA. To overcome this, the researchers employed a homologous recombination strategy to manually insert an artificial attB site into the K. aridum chromosome.
This artificial "landing pad" transformed the genetically recalcitrant organism into a programmable chassis, allowing for the stable integration and expression of multiple genes driven by the strong, constitutive kasOP* promoter.
Synergistic Effects of orf10 and orf11
The study systematically evaluated the impact of overexpressing different enzymes to identify the most effective combination:
- Halogenases (orf10 and vcm8): Overexpression of orf10 was found to primarily increase the ratio (purity) of the B component by facilitating the conversion of A and C analogs into B.
- Glycosyltransferases (orf11, orf12, orf13): Overexpression of orf11 (glycosyltransferase A) primarily increased the total titer (yield) of the products.
The most effective strategy involved the simultaneous overexpression of both orf10 and orf11 in the engineered strain SIPI-3927-C6. This approach addressed both the specific pathway bottleneck and the overall metabolic flux, leading to synergistic improvements in both yield and purity.
Key Results and Industrial Potential
The performance of SIPI-3927-C6 was validated in a 5-L fermenter using controlled glucose feeding and pH regulation. The results demonstrated a dramatic improvement over the parent strain:
- Yield: A82846B titer increased from 1013 mg/L to 2520 mg/L (a 2.5-fold boost).
- Purity: The ratio of the "B" component rose from 38.9% to 86.5%.
- Impurity Reduction: The unwanted "A" component was reduced to 13.4%, and the "C" component was nearly eliminated (0.1%).
The integrated genes remained stable for at least six generations, confirming the robustness of the artificial attB integration strategy for long-term industrial fermentation.
Conclusion
This work demonstrates that artificial attB sites are effective tools for metabolic engineering in organisms lacking natural integration sites. By targeting both halogenation and glycosylation steps, the researchers successfully created a high-performing industrial strain for A82846B production, significantly reducing the burden of downstream purification and potentially lowering the cost of Oritavancin manufacturing.
Summary updated